Pharmacists must take time to understand why patients are not adherent to HIV pre-exposure prophylaxis (PrEP) and what barriers exist, said Kevin N. Astle, PharmD, BCPS, BCACP, AAHIVP, CDES, assistant professor at the University of South Florida Taneja College of Pharmacy.
Kevin N. Astle, PharmD, BCPS, BCACP, AAHIVP, CDES, assistant professor at the University of South Florida Taneja College of Pharmacy, talks about the pharmacist's role in educating patients on HIV risk and promoting pre-exposure prophylaxis (PrEP) adherence.
Transcript
What is the pharmacist’s role in making PrEP therapies available to people at high risk of contracting HIV?
The biggest role that pharmacists can have is educating patients about their risk level. I think right now there's a big community-wide knowledge gap about what the risk factors are and who would benefit from PrEP, so as pharmacists, we can be patient facing, we can do a lot of education within the community. We're also seeing a lot of states are passing collaborative practice agreements and PrEP protocols for pharmacists to be able to prescribe PrEP and continue therapy for patients. So I think really expanding access where possible.
What is their role in promoting adherence?
Very similar. As pharmacists, we're able to see what prescriptions patients are filling, how often they're coming in to get their refills. So, [we're] really able to help keep patients on track with their medications, identifying any gaps. We can reach out and understand where the nonadherence comes from. I think that's a big concern. We learn that adherence is an issue, and a lot of times we'll just label the patient is either nonadherent or they're not taking their medicine. We need to take the time to understand why they're not taking their medications and what barriers there are. I think pharmacists are really instrumental in that role.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More